





EXPLORING THE ROLE OF MITOCHONDRIAL DNA QUANTITY AND QUALITY 








A dissertation submitted to Johns Hopkins University  








© 2019 Ryan Longchamps 




Mitochondria represent an essential component of healthy aging, in part due to their 
critical role in cellular metabolism. Declines in mitochondrial function have been linked to 
several aging-related diseases, such as cardiovascular disease (CVD). Although many risk 
factors for CVD are have been fully elucidated, understanding the underlying role of 
mitochondrial function in CVD etiology may reveal untapped avenues for clinical testing 
and treatment. We begin to approach this issue by tackling two novel biomarkers of 
mitochondrial function: mitochondrial DNA (mtDNA) quantity and quality. First, we 
examine the impact of mtDNA quantity estimation methods on outcomes to establish a 
new gold standard for this novel phenotype. We then perform the largest genome-wide 
association study for mtDNA quantity to date and identify putative loci controlling mtDNA 
quantity. With these loci we discover previously unidentified pathways which may 
contribute to control of mtDNA quantity and may explain its link to mitochondrial 
function. In the final part of this work we examine the impact of poor mtDNA quality on 
mortality and incident CVD. We establish accumulated mtDNA mutations as a risk factor 
of mortality and CVD, independent of traditional risk factors. Finally, we assess how the 
mutational burden of mtDNA mutations modulates risk for mortality and CVD. 
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Chapter 1 : Introduction 
 
MITOCHONDRIAL DYSFUNCTION IN DISEASE 
The mitochondrion is double membraned organelle involved in several cellular 
processes such as intracellular signaling, reactive oxygen species (ROS) production, 
cellular differentiation and apoptosis. However, the primary function of the mitochondrion 
is known as oxidative phosphorylation whereby the chemical energy required for cellular 
metabolism is created. Oxidative phosphorylation occurs within the mitochondrial cristae 
where the major byproducts of the citric acid cycle, NADH and FADH2, are oxidized to 
generate a proton gradient which is subsequently used to generate ATP. Due to its integral 
role in energy supply, mitochondrial dysfunction and declines in oxidative capacity have 
long been hypothesized to underlie critical changes which increase vulnerability to chronic 
disease1–3.  
Of interest to our lab, mitochondrial dysfunction has specifically been linked to 
cardiovascular disease (CVD)4, one of the leading causes of mortality and morbidity in the 
United States. CVD represents a complex cluster of diseases of the blood vessels and heart 
that often reveals clinically as myocardial infarction and stroke. In spite of its heterogenous 
nature, CVD is typically driven by endothelial damage and a subsequent chronic 
inflammatory response known as atherosclerosis where a buildup of fats and cholesterol 
creates arterial plaques which can restrict blood flow or burst. Mitochondrial dysfunction 
has been linked to atherosclerosis by affecting plaque instability and blood clot formation 
through changes in ROS production, apoptosis and intracellular signaling5,6. Additionally, 
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mitochondrial dysfunction in mice mediated by mitochondrial DNA (mtDNA) damage 
demonstrated increased a larger necrotic core and thinner fibrous cap, key features of 
plaque instablility7. Furthermore, increased ROS production has been linked to endothelial 
senescence8,9 and loss of endothelial integrity10, possibly highlighting a role where 
mitochondrial dysfunction contributes to the initiation of atherosclerosis. 
Although several pathways through which mitochondrial dysfunction acts on CVD 
have been explored, several questions have yet to be answered. In this work, we hope to 
address some of these questions by interrogating two minimally invasive biomarker of 
mitochondrial function: mtDNA quantity11 and mtDNA quality12. 
 
MITOCHONDRIAL DNA QUANTITY 
Unlike most organelles, the mitochondrion possesses its own genome, an intron-
free, double-stranded, 16.6 kb maternally inherited, circular DNA molecule with 37 genes 
vital to oxidative phosphorylation. The term mtDNA quantity, also known as mtDNA copy 
number (mtDNA-CN), is in reference to the fact that a large amount of variation exists in 
the number of copies of mtDNA present within cells, tissues, and individuals. Several 
methods exist in which to measure mtDNA-CN, however with the advent of several newer 
methods there has yet to be a rigorous examination of these methods to establish a new 
gold standard. Without a comprehensive comparison several researchers may be relying on 
suboptimal methods resulting in misrepresented associations involving mtDNA-CN. Here, 
we approach this issue by performing an intrinsic validation to provide the field with 
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qualitative information on the performance of five common mtDNA-CN estimation 
methods. 
Previous research has demonstrated mtDNA-CN directly correlates with 
mitochondrial function as measured through energy reserves, oxidative stress, and 
mitochondrial membrane potential13. In fact, previous work from our lab has demonstrated 
individuals in the lowest 20th percentile of mtDNA-CN were 23% more likely to develop 
CVD compared to individuals in the highest 20th percentile14. Additionally, we were able 
to improve 10-year CVD risk classification when mtDNA-CN was added to the Pooled 
Cohort Equation from the 2013 American College of Cardiology/American Heart 
Association guideline on assessment of CVD risk. Importantly, these findings were 
independent of traditional risk factors indicating mtDNA-CN may be acting orthogonal to 
these factors in an independent pathway. 
In this work, we take a population genetics approach to exploring how mtDNA-CN 
is associated with CVD independent of traditional risk factors. Although several Mendelian 
mitochondrial disorders have identified genes which modulate mtDNA-CN, the 
comprehensive mechanism through which copy number is regulated is largely unknown15. 
To further identify the genetic factors which control mtDNA-CN, we leverage data from 
the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) 
consortium and the UK Biobank to perform a genome-wide association study (GWAS). 
With more mtDNA-CN loci identified we identify pathways and biological processes 
which correlate with mtDNA-CN as a means to better understand the role mtDNA-CN 
plays in CVD.  
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MITOCHONDRIAL DNA QUALITY 
In addition to mtDNA-CN, mtDNA quality, or an accumulation of mtDNA 
mutations, has also been shown to be a useful biomarker for mitochondrial function12. As 
a natural byproduct of oxidative phosphorylation, ROS lead to mtDNA damage and 
declines in mitochondrial respiratory activity16. These subsequent declines to 
mitochondrial respiration could further exacerbate ROS levels resulting in a negative 
feedback loop of mitochondrial dysfunction. In fact, oxidative damage has been shown to 
markedly increase with age17,18 showing the importance of this negative feedback loop. 
Furthermore, oxidative stress induced mtDNA damage persists longer than nuclear DNA 
damage highlighting the long term effects mtDNA damage can have on subsequent gene 
expression19.  
Previous research has focused on exploring the impact of specific mtDNA 
mutations, or heteroplasmies, on mitochondrial function and disease. For example, 
m.3243A > G, a mutation within the mitochondrial tRNA leucine, has been widely studied 
and linked to mortality, dementia, stroke20, and carotid artery dissection21. However, little 
is known about the overall heteroplasmic burden, or DNA quality, on disease. With the 
wider availability of whole genome sequence data, we are no longer limited to asking 
questions about single heteroplasmic sites. Instead, we can assess an individual’s risk based 
on heteroplasmies found across the entire mtDNA genome. As such, in the final part of this 
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Mitochondrial dysfunction has long been known to play an important role in the 
underlying etiology of several aging-related diseases, including cardiovascular disease 
(CVD), neurodegenerative disorders and cancer4. As an easily measurable and accessible 
proxy for mitochondrial function, mitochondrial DNA copy number (mtDNA-CN) is 
increasingly used to assess the role of mitochondria in disease. Several population-based 
studies have shown higher levels of mtDNA-CN to be associated with decreased incidence 
for CVD and its component parts: coronary artery disease (CAD) and stroke14,22; 
neurodegenerative disorders such as Parkinson’s and Alzheimer’s23,24; as well as several 
types of cancer including breast, kidney, liver and colorectal25–27. Furthermore, mtDNA-
CN measured from peripheral blood has consistently been shown to be higher in women, 
decline with age, and correlate negatively with white blood cell (WBC) count28–30.  
Although the mtDNA-CN field is relatively young, the number of publications has 
been steadily increasing at an average rate of 12% per year since 201531. However, there 
has yet to be a rigorous examination of the various methods for measuring this novel 
phenotype and the factors which may influence its accurate estimation. Without such an 
examination, studies may be severely underestimating or misrepresenting the relationship 
of mtDNA-CN with their traits of interest. 
Quantitative real-time PCR (qPCR) has been the most widely used method for 
measuring mtDNA-CN, partly due to its low cost and quick turnaround time. However, 
recent work has demonstrated the feasibility of accurately measuring mtDNA-CN from 
preexisting microarray, whole exome sequencing (WES) and whole genome sequencing 
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(WGS) data14,29,32. With these advances, it is important for the field to evaluate these 
methods in the context of the current gold standard.  
In addition to the method for determining mtDNA-CN, it is important to consider 
the impact of DNA extraction method on mtDNA-CN, particularly due to the small size 
and circular nature of the mitochondrial genome. Previous research has shown organic 
solvent extraction is more accurate than silica-based methods at measuring mtDNA-CN, 
which is unsurprising as column kit parameters are typically optimized for DNA fragments 
≥ 50 Kb33. However, as all DNA extraction methods have bias in the DNA which they 
target, measuring mtDNA-CN from direct cell lysate may prove to be a more accurate 
method. 
In the present study, we assess the relative performance of various methods for 
measuring mtDNA-CN and the effects of DNA extraction on mtDNA-CN estimation 
accuracy. We leverage mtDNA-CN calculated across 4,574 individuals from two 
prospective cohorts, the Atherosclerosis Risk in Communities study (ARIC) and the Multi-
Ethnic Study of Atherosclerosis (MESA). Using mtDNA-CN estimates calculated from 
qPCR, WES, WGS, and two microarray platforms – the Affymetrix Genome-Wide Human 
SNP Array 6.0 and the Illumina HumanExome BeadChip genotyping array – we compare 
associations for known correlates of mtDNA-CN including age, sex, white blood cell 
count, the Duffy locus and incident CVD to  determine the optimal method for calculating 
copy number. We additionally determined the reproducibility of mtDNA-CN 
measurements in vitro from three separate DNA extraction methods: silica-based column 
selection, organic solvent extraction (phenol-chloroform-isoamyl alcohol), and measuring 
mtDNA-CN from direct cell lysis without performing a traditional DNA extraction. We 
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hypothesized that mtDNA-CN calculated from WGS data would outperform other 
estimation methods and mtDNA-CN measured from direct cell lysate would be more 
accurate than traditional DNA extraction methods. 
METHODS 
Study populations 
The ARIC study recruited 15,792 individuals between 1987 and 1989 aged 45 to 
65 years from 4 US communities. DNA for mtDNA-CN estimation was collected from 
different visits and was derived from buffy coat using the Gentra Puregene Blood Kit 
(Qiagen). Our analyses were limited to 1,085 individuals with mtDNA-CN data available 
across all four platforms performed within ARIC: Affymetrix Genome-Wide Human SNP 
Array 6.0, Illumina HumanExome BeadChip genotyping array, WES and WGS. Eighty-
eight percent of our final ARIC participants were African American.  
The MESA study recruited 6,814 individuals free of prevalent clinical CVD from 
6 US communities across 4 ethnicities. Age range at baseline was 45 to 84 and the baseline 
exam occurred between 2000 and 2002. DNA for mtDNA-CN analyses was isolated from 
exam 1 peripheral leukocytes using the Gentra Puregene Blood Kit. Our analyses were 
restricted to 3,489 white and African American (36%) individuals with mtDNA-CN data 
available across the three platforms with mtDNA-CN data available at the time of analysis: 
qPCR, Affymetrix Genome-Wide Human SNP Array 6.0 and Illumina HumanExome 
BeadChip genotyping array.  
All participants provided written informed consent and all centers obtained 
approval from their respective institutional review boards. 
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Measurement of mtDNA-CN 
qPCR 
mtDNA-CN was determined using a multiplexed real time qPCR assay as 
previously described30. Briefly, the cycle threshold (Ct) value of a mitochondrial-specific 
(ND1) and nuclear-specific (RPPH1) target were determined in triplicate for each sample. 
The difference in Ct values (ΔCt) for each replicate represents a raw relative measure of 
mtDNA-CN. Replicates were removed if they had Ct values for ND1 > 28, Ct values for 
RPPH1 > 5 standard deviations from the mean, or ΔCt values > 3 standard deviations from 
the mean of the plate. Outlier replicates were identified and excluded for samples with a 
ΔCt standard deviation > 0.5. The sample was excluded if the ΔCt standard deviation 
remained > 0.5 after replicate removal. We corrected for an observed linear increase in ΔCt 
value due to the pipetting order of each replicate via linear regression. The mean ΔCt across 
all replicates was further adjusted for plate effects as a random effect to represent a raw 
relative measure of mtDNA-CN. 
 
Microarray 
mtDNA-CN was determined using the Genvisis34 software package for both the 
Affymetrix Genome-Wide Human SNP Array 6.0 and the Illumina HumanExome 
BeadChip genotyping array. A list of high-quality mitochondrial SNPs were hand-curated 
by employing BLAST to remove SNPs without a perfect match to the annotated 
mitochondrial location and SNPs with off-target matches longer than 20bp. The probe 
intensities of the remaining mitochondrial SNPs (25 Affymetrix, 58 Illumina Exome Chip) 
were determined using quantile sketch normalization (apt-probeset-summarize) as 
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implemented in the Affymetrix Power Tools software. The median of the normalized 
intensity, log R ratio (LRR) for all homozygous calls was GC corrected and used as initial 
estimates of mtDNA-CN for each sample. 
Technical covariates such as DNA quality, DNA quantity, and hybridization 
efficiency were captured via surrogate variable analysis or principal component analysis 
as previously described14. Surrogate variables or principal components were applied to the 
BLAST filtered, GC corrected LRR of the remaining autosomal SNPs (43,316 Affymetrix, 
47,512 Exome Chip).  
These autosomal SNPs were selected based on the following quality filters: call rate 
> 98%, HWE p value > 0.00001, PLINK mishap for non-random missingness p value > 
0.0001, association with sex p value > 0.00001, linkage disequilibrium pruning (r2 < 0.30), 
with maximal spacing between autosomal SNPs of 41.7 kb. 
 
Whole Exome Sequencing 
Whole exome capture was performed using Nimblegen’s VChrome2.1 (Roche) and 
sequencing was performed on the Illumina HiSeq 2000. Sequence reads were aligned using 
Burrows-Wheeler Aligner (BWA)35 to the hg19 reference genome. Variant calling, and 
quality control were performed as previously described36. mtDNA-CN was calculated 
using the mitoAnalyzer software package, which determines the observed ratios of 
sequence coverages between autosomal and mtDNA37,38.  
Due to large batch effects observed in our raw mtDNA-CN calls, alignment 
summary, insert size, quality score, base distribution, sequencing artifact and quality yield 
metrics were collected using Picard tools (version 1.87) to take into account differences in 
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capture efficiency as well as sequencing and alignment quality39. Picard sequencing 
summary metrics to incorporate into our final model were selected through a stepwise 
backwards elimination model (Supplementary Table 2.1). 
 
Whole Genome Sequencing 
Whole genome sequencing data was generated at the Baylor College of Medicine 
Human Genome Sequencing Center using Nano or PCR-free DNA libraries on the Illumina 
HiSeq 2000. Sequence reads were mapped to the hg19 reference genome using BWA35. 
Variant calling and quality control were performed as previously described40. A count for 
the total number of reads in a sample was scraped from the NCBI sequence read archive 
using the R package RCurl41 while reads aligned to the mitochondrial genome were 
downloaded directly through Samtools (version 1.3.1). A raw measure of mtDNA-CN was 
calculated as the ratio of mitochondrial reads to the number of total aligned reads. Unlike 
WES, we did not observe large batch effects in our WGS raw mtDNA-CN calls, obviating 
the need for adjustment for Picard sequencing summary metrics. 
 
Genotyping and imputation 
Genotype calling for the WBC count locus was derived from the Affymetrix 
Genome-wide Human SNP Array 6.0 in ARIC and MESA. Haplotype phasing for both 
cohorts was performed using ShapeIt42 and imputation was performed using IMPUTE243. 
Genotypes were imputed to the 1000G reference panel (Phase I, version 3). Imputation 




DNA extraction method 
All DNA used in the DNA extraction comparison were derived from HEK293T 
cells grown in a single 150T flask to minimize variation due to clonality and cell culture 
procedures. Extraction were performed with 15 replicates each containing one million 
cells. mtDNA-CN was determined using qPCR as described previously. To account for the 
inherent variability in mtDNA-CN estimation, qPCR was run in triplicate.  
 
Silica-base column extraction 
We performed a silica-based column extraction using the AllPrep DNA/RNA Mini 
Kit (Qiagen) according to the manufacturer’s instructions for fewer than 5 x 106 cells. 
Briefly, HEK293T cells were lysed and the subsequent lysate was pipetted directly onto 
the DNA Allprep spin column for homogenization and DNA binding. The bound DNA 
was then washed and eluted. 
 
Organic solvent extraction 
An aliquot of cells were lysed with 350 µL of RLT Plus Buffer (Qiagen) and one 
volume of phenol:chloroform:isoamyl alcohol (25:24:1) (PCIAA) was added to the sample 
and mixed until it turned milky white. The solution was centrifuged and the upper aqueous 
phase containing DNA was transferred to a separate tube. We proceeded with an ethanol 





Direct cell lysis 
Cells were pelleted at 500g for 5 minutes and the supernatant was removed. The 
cell pellet was agitated in 100 µL of QuickExtract DNA Solution (Lucigen) to disrupt the 
pellet and placed in a thermocycler for 15 minutes at 68°C followed by 10 minutes at 95°C. 
The lysate was then centrifuged at 17,000g for 15 minutes to pellet any insoluble inhibitors 
and the supernatant was transferred to a clean tube. The supernatant containing DNA was 
finally diluted 1:30 with water to limit the impact of any soluble inhibitors on qPCR. 
 
Statistical analyses 
Our final mtDNA-CN phenotype for all measurement techniques is represented as 
the standardized residuals from a linear model adjusting the raw measure of mtDNA-CN 
for age, sex, DNA collection center, and technical covariates. Additionally, mtDNA-CN in 
ARIC was adjusted for WBC count, and the14.9% of individuals with missing WBC data 
were imputed to the mean. WBC was not available in MESA for the same visit in which 
the DNA was obtained. As mtDNA-CN was standardized, the effect size estimates are in 
units of standard deviations, with positive betas corresponding to an increase in mtDNA-
CN.  
For analyses involving outcomes which also served as covariates in our final 
phenotype model (age, sex, WBC count), mtDNA-CN was calculated using the full model 
minus the outcome variable. For example, when exploring the relationship between 
mtDNA-CN and age, our mtDNA-CN phenotype would represent the standardized 
residuals from a model controlling for sex, sample collection center, WBC count and any 
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technical covariates. We would then use this phenotype to explore the association between 
age and mtDNA-CN such that effect sizes for all comparisons remain in standard deviation 
units.  
Single SNP regression for mtDNA-CN on the WBC count locus was performed in 
blacks with FAST44. In ARIC, mtDNA-CN not adjusted for WBC count was used as the 
independent variable. Single SNP regression models were additionally adjusted for age, 
sex, sample collection site, and genotyping PCs.  
Cox-proportional hazards regression was used to estimate hazard ratios (HRs) for 
incident CVD outcomes. Follow-up time was defined from DNA collection through death, 
loss to follow-up, or study end point (through 2017 in ARIC and 2015 in MESA). Pairwise 
F-tests were used to test the null hypothesis that the ratio of variances between the DNA 
extraction methods is equal to one. All analyses were performed using R (version 3.3.3).  
RESULTS 
The study included 1,085 participants from ARIC with mtDNA-CN data from the 
Affymetrix 6.0 microarray, the Illumina Exome Chip microarray, WES, and WGS while 
MESA included 3,489 participants with mtDNA-CN data available from qPCR, the 
Affymetrix 6.0 microarray, and the Illumina Exome Chip microarray (combined N = 
4,574). The mean age of study participants was 61.4 years (ARIC, 57.1 years; MESA 62.7 
years), 55.3% of participants were female (n = 2,528), and 46.4% of participants were black 
(n = 2,124) (Table 2.1). While the Affymetrix and Illumina Exome Chip arrays were run 
in both cohorts, at the time of analysis WES and WGS were unique to ARIC and qPCR 
was unique to MESA. 
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mtDNA-CN estimation method comparison 
To determine the optimal method for measuring mtDNA-CN, we ranked the 
performance of each technique based on strength of the association, as measured by p 
values, with the relevant mtDNA-CN correlate (Supplementary Table 2.2). Kendall’s W 
tests45 show significant agreement in rankings across correlates in ARIC (p = 0.0019, 
Kendall’s W = 0.79) and MESA (p = 0.036, Kendall’s W = 0.82) with WGS and the 
Affymetrix array performing best for each measure in ARIC and MESA, respectively 
(Table 2.2).  
To additionally quantify performance, we created a scoring system for each method 
using negative log transformed p values standardized to the least significant method for 
each correlate. These values were then summed across the correlates for each method to 
achieve an overall rating of performance (Supplementary Table 2.3).  These ratings were 
compared to 1,000 permutations of a random sampling of the standardized and transformed 
p values for each correlate across the different estimation techniques. In ARIC, WGS had 
a significantly higher performance score compared to all other methods (p < 0.002) while 
the Illumina Exome Chip had a significantly lower score (p = 0.03) (Supplementary 
Figure 2.1A). In MESA, Affymetrix had a significantly higher score than qPCR and the 
Illumina Exome Chip (p = 0.002) (Supplementary Figure 2.1B). When removing the 
contribution of WGS in ARIC, the Affymetrix array had a significantly higher score than 
the Illumina Exome Chip and WES (p = 0.01) (Supplementary Figure 2.1C). 
As WGS and Affymetrix performed similarly, we sought to further parse out their 
performance by evaluating the 2,746 ARIC samples which contained mtDNA-CN from 
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both platforms. On average, WGS performed 2.2 orders of magnitude more significantly 
than the Affymetrix array (Supplementary Table 2.4). 
 
DNA extraction comparison 
Raw mitochondrial estimates from qPCR were mean-zeroed to the plate average 
and the mean value across the triplicate plates was used to determine the variance across 
the 15 replicates for each method (Fig 2.1). The variance for our novel Lyse method was 
significantly lower at 0.02 compared to 0.17 and 0.59 for the PCIAA and Qiagen Kit 
extractions respectively (F = 0.13, p = 5.44x10-4; F = 0.04, p = 2.82x10-7). Additionally, 
our findings support previous work33 demonstrating PCIAA had significantly lower 
variability compared to the Qiagen Kit (F = 0.29, p = 0.03). 
DISCUSSION 
We explored several methods for measuring mtDNA-CN in 4,574 self-identified 
white and black participants from the ARIC and MESA studies. We found mtDNA-CN 
estimated from WGS read counts and Affymetrix Genome-Wide Human SNP Array 6.0 
probe intensities was more significantly associated with known mtDNA-CN correlates 
compared to mtDNA-CN estimated from WES, qPCR and the Illumina HumanExome 
BeadChip. When observing the relative performance of these methods, mtDNA-CN 
calculated from either WGS or Affymetrix array are, respectively, 5.6 and 5.4 orders of 
magnitude more significant than the current gold standard of qPCR (Figure 2.2). These 
results are not limited to significance as we see similar trends when exploring effect size 
estimates (Figure 2.3). For example, when looking at incident CVD, mtDNA-CN 
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measured from WGS observes a substantial HR of 0.63 (0.54 – 0.74) where as mtDNA-
CN measured from qPCR only has a HR of 0.93 (0.82 – 1.05), a marked difference. As a 
result, when exploring the relationship between mtDNA-CN and a trait of interest, on 
average one could expect a result 5.6 orders of magnitude less significant and 6 times less 
extreme when using mtDNA-CN estimated from qPCR data as opposed to WGS.  
Interestingly, mtDNA-CN measured from two seemingly similar microarray 
platforms differed drastically (Supplementary Figure 2.2). However, this finding is 
unsurprising when exploring the underlying biochemistry of sample preparation for each 
microarray platform. While the Affymetrix protocol starts with two restriction enzyme 
digests prior to whole genome amplification (WGA), the Illumina Exome Chip requires 
WGA with a processive polymerase prior to sonication. As a result, the mitochondrial 
genome undergoes rolling circle amplification which occurs at a significantly faster rate 
than linear WGA46. 
Lower mtDNA-CN has been found to be associated with an increased incidence for 
several diseases, including end stage renal disease, type 2 diabetes, and non-alcoholic fatty 
liver disease47–49. However, such studies have relied on mtDNA-CN estimated from qPCR 
data. Our findings suggest much of the current literature may be severely underestimating 
disease associations with mtDNA-CN as well as its potential as a predictor of disease 
outcomes. Despite this, at <$2 per sample qPCR may remain the principal method for 
measuring mtDNA-CN due to the prohibitive costs of WGS. As a result, it may be time for 
the field to start exploring other low cost methods, such as digital droplet PCR, which may 
improve upon the accuracy of qPCR50,51. 
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We additionally showed DNA extraction method affects mtDNA-CN estimate 
reproducibility with copy number measured directly from cell lysate significantly 
outperforming silica-based column extraction and organic solvent extraction. Although 
several other studies have explored the impact of DNA isolation protocol on mtDNA-CN 
estimation33,52,53, to our knowledge, this is the first study to interrogate the possibility of 
measuring mtDNA-CN directly from cell lysate. In addition to the superior performance 
of direct cell lysis, this method is cheaper and has less hands-on time than PCIAA or 
Qiagen Kit extractions. However, the authors recognize DNA from cell lysate has less 
downstream utility than traditional DNA extraction procedures potentially limiting its 
adoption within the mtDNA-CN field when sample availability is limited. Furthermore, it 
is important to note the various DNA extraction methods resulted in significantly different 
mtDNA-CN estimates (p = 3.56x10-11, 0.02, 2.85x10-7 for Lyse:PCIAA, Lyse:Qiagen Kit, 
and PCIAA:Qiagen Kit respectively). As such, when choosing an extraction method, it is 
important to remain consistent across the study. 
In conclusion, our study demonstrates mtDNA-CN calculated from WGS reads or 
Affymetrix microarray probe intensities significantly improves upon the current gold 
standard method of qPCR. Furthermore, we show direct cell lysis introduces less variability 
to mtDNA-CN estimates than popular DNA extraction methods. Despite the relative 
infancy of using mtDNA-CN as a novel risk marker, these findings highlight the need for 
the field to adapt to current technologies to ensure disease and trait associations are fully 
realized with a move toward more accurate microarray and WGS methods. Furthermore, 
due to the prevalence of qPCR in the literature, the authors recommend re-analyzing trait 
associations as more WGS data becomes available from large initiatives such as TOPMed.  
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Table 2.1. Participant characteristics 
Values are number (%) or mean ± SD  
Abbreviations: SD, standard deviation; WBC, white 




















Table 2.2. Performance rankings for mtDNA-CN estimation methods 



















































Figure 2.1. mtDNA-CN measured across DNA extraction methods. 
mtDNA-CN measured by qPCR was mean-zeroed and averaged across three 
runs for Lyse, PCIAA and Qiagen Kit DNA extractions. Variance for Lyse, 









































Figure 2.2. Relative overall performance of mtDNA-CN estimation methods. 
Overall performance for each method scored as mean or median of the negative log-
transformed p value across all correlates normalized to the least significant method of 
each correlate. For ExomeChip and Affymetrix, the mean value across both cohorts 





Figure 2.3. Effect size and Hazard Ratio estimates for mtDNA-CN with 
known correlates. Data points and their corresponding 95% confidence intervals 
represent the effect size or Hazard Ratio estimates for mtDNA-CN with Age, Sex, 
WBC count, Duffy locus, and incident Cardiovascular Disease. Effect size 
estimates are in standard deviation units. The significance of each estimate is 
represented as ‘*’ for P < 0.05, ‘**’ for P < 0.01, and ‘***’ for P < 0.001. WBC, 































Supplementary Table 2.2. Associations of known correlates with mtDNA-CN estimation Platforms 

































*Duffy locus associations were performed in blacks only 













































A Supplementary Figure 2.1. 
Permutation test for mtDNA-CN 
estimation method performance 
Performance scored as sum of 
negative log-transformed p value 
for each method across all 
correlates normalized to the least 
significant method of each 
correlate. Compared to 1,000 
permutations of the sums of 
randomly selected normalized and 
transformed p values. ARIC (A), 















*Duffy locus associations were performed in blacks only 



























Supplementary Figure 2.2. Phenotype correlation 
plots. ARIC (A) and MESA (B) 
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Chapter 3 : 
A genome-wide association study of 
mitochondrial DNA copy number in 79,444 





Unlike the nuclear genome, a large amount of variation exists in the number of 
copies of mtDNA present within cells, tissues, and individuals. The relative copy number 
of mtDNA (mtDNA-CN) has been shown to directly correlate with oxidative stress, energy 
reserves, and mitochondrial membrane potential13. As a minimally invasive proxy measure 
of mitochondrial dysfunction11, mtDNA-CN has been previously associated with several 
disease states including frailty30, cardiovascular disease (CVD)14, chronic kidney disease54, 
neurodegeneration23,24, and cancer25.  
Although the comprehensive mechanism through which mtDNA-CN is modulated 
is largely unknown15,55, several genes have been shown to influence mtDNA-CN. Proteins 
within the mtDNA replication machinery directly modulate mtDNA-CN, including those 
of the mitochondrial polymerase, POLG and POLG2,56,57 as well as the mitochondrial 
DNA helicase, C10orf2, and the mitochondrial single-stranded binding protein, mtSSB58. 
TFAM initiates mtDNA replication and is a common target for in vivo studies looking to 
modulate mtDNA-CN32,59. Furthermore, genes which maintain proper mitochondrial 
nucleotide supply including DGUOK and TK2 have also been shown to regulate mtDNA-
CN60,61. However, the impact of these genes on mtDNA-CN were discovered through 
Mendelian mitochondrial diseases and do not sufficiently represent the large number of 
loci which likely control a complex phenotype such as mtDNA-CN.  
To date, several genome-wide association studies (GWAS) of mtDNA-CN have 
been published, unfortunately due to their limited sample sizes few genome-wide 
significant loci have been identified32,62,63. In a GWAS of 10,442 Han Chinese women 
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recruited through the China, Oxford, and Virginia Commonwealth University 
Experimental Research on Genetic Epidemiology (CONVERGE) consortium, Cai et al. 
found two putative loci which control mtDNA-CN32. Their first hit occurred within the 3’ 
region of TFAM, a gene already known to regulate mtDNA replication, while their second 
hit occurred within the first intron of CDK6, a gene which has not been previously 
implicated in mtDNA-CN. These findings were further replicated by 1,753 individuals of 
the Avon Longitudinal Study of Parent and Children (ALSPAC) study. In spite of these 
findings, given the polygenic nature of many complex phenotypes, the field is most likely 
only scratching the surface in terms of genes which contribute to mtDNA-CN variation. 
In this study we leverage mtDNA-CN measured in 79,444 individuals across six 
prospective cohorts and four ethnicities to perform the largest mtDNA-CN GWAS to date. 
We additionally validate loci from previous studies and perform gene ontology and 
pathway analysis to identify novel networks which may regulate mtDNA-CN.  
 
METHODS 
All participants provided written informed consent and all centers obtained 
approval from their respective institutional review boards. Detailed cohort descriptions and 






Estimation of Mitochondrial DNA Copy Number 
qPCR 
mtDNA-CN was determined using a multiplexed real time qPCR assay as 
previously described64. Briefly, the cycle threshold (Ct) value of a nuclear-specific 
(RPPH1) and mitochondrial-specific (ND1) probe were measured in triplicate for each 
sample. In addition to plate effects, we observed a linear increase in ΔCt due to the pipetting 
order of each replicate. We corrected for these effects by mixed linear regression whereby 
pipetting order was a fixed effect and plate was a random effect. 
 
Microarray 
Microarray probe intensities were used to estimate mtDNA-CN using the Genvisis 
software package as previously described14,34,64. Briefly, the mitochondrial probe 
intensities were determined using quantile sketch normalization (apt-probeset-summarize) 
as implemented in the Affymetrix Power Tools software65. The median of the log R ratio 
normalized probe intensity for all homozygous calls was GC corrected and used as initial 
estimates of mtDNA-CN. Technical artifacts such as DNA quality and DNA quantity were 
captured via surrogate variable analysis or principal component analysis. 
 
Whole Exome Sequencing 
Detailed methods for estimating mtDNA-CN from UK Biobank whole exome 
sequencing read counts can be found in the Supplementary Material. Briefly, a linear 
regression model was used to adjust mtDNA read count for total, unknown, decoy1 and 
decoy2 read counts. Residuals from this model were then further adjusted for age, sex, 
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platelet count and neutrophil count to represent a final measure of mtDNA-CN 
(Supplementary Table 3.1). 
 
Whole Genome Sequencing 
Whole genome sequencing read counts were used to estimate mtDNA-CN as 
previously described64. Briefly, the total amount of reads in a sample was scraped from the 
NCBI sequence read archive. Mitochondrial reads were downloaded directly through 
Samtools (1.3.1). A ratio of mitochondrial reads to total aligned reads was used as a raw 
measure of mtDNA-CN. 
 
Adjusting for covariates 
The final mtDNA-CN phenotype is represented as the standardized residuals (mean 
= 0, standard deviation = 1) from a linear model adjusting for known influences on 
mtDNA-CN including age, sex, and DNA collection site. Estimates from ARIC, SHIP, and 
CHS were additionally adjusted for white blood cell count. Details on covariate adjustment 
for UKB is available within the Supplementary Material. 
 
Genome-wide association study 
Each study performed regression analysis with mtDNA-CN as the dependent 
variable adjusting for age, sex, white blood cell count (if applicable), and cohort-specific 
covariates (principal components, DNA collection site, family structure). Race stratified 
meta-analyses were performed with Metasoft66 with random effects models to control for 
unobserved heterogeneity due to differences in mtDNA-CN estimation method between 
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studies. Similarly, trans-ethnic meta-analyses were conducted with a random effects model 
via Metasoft. Effect size estimates for SNPs were calculated via standard inverse variance-
weighted meta-analysis using cohort summary statistics.  
 
GO/KEGG 
Gene-based testing with 50 kb windows around each gene was performed with 
VEGAS267. Gene Ontology (GO)68,69 and Kyoto Encyclopedia of Genes and Genomes 
(KEGG)70,71 analyses were performed using gene-based testing results. We performed 9 
stepwise cutoffs of input genes ranging from 100 to 500 as well as 1,000 permutation tests 
to ensure robustness of results. 
RESULTS 
Sample characteristics 
The study included 79,444 individuals (54.9% female) across four ethnicities (6.0% 
Black, 1.0% Chinese, 1.5% Hispanic) (Table 3.1). A majority of the data originated from 
the UK Biobank (56.4%) and consisted of mtDNA-CN derived from WES. mtDNA-CN 
estimated from the Affymetrix array consisted of 39.0% of the data while qPCR-derived 
mtDNA-CN consisted of only 4.6% of the data. 
 
Genome-wide association study 
Trans-ethnic meta-analysis reveals four novel genome wide significant loci (Figure 
3.1, Table 3.2, Supplementary Figure 3.1). The lead SNP of the NDUFV3 locus 
(rs4148974) occurs within exon 3 of NDUFV3 and the lead SNP of the REEP3 locus 
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(rs7895549) occurs within the 3rd intron of REEP3 while the other two loci are intergenic. 
Manhattan/QQ plots for ethnicity specific GWAS available in Supplementary Figures 
3.2A-D, 3.3A-D. 
In an attempt to validate previous findings, we validate the TFAM (rs11006126) 
and CDK6 (rs445) loci from the Cai et al. GWAS (Table 3.3). The SNP rs445 was 
significantly associated with mtDNA-CN in our GWAS (p value = 1.33 x 10-4) while 
rs11006126 was only nominally associated with mtDNA-CN (p value = 0.059). Our effect 
size estimates are considerably smaller than those found in the CONVERGE and ALSPAC 
studies, however this is most likely due to different standardizations of the mtDNA-CN 
phenotype. Whereas the Cai et al. paper transformed mtDNA-CN to normality by quantile-
normalization after adjusting for covariates, we standardized our phenotype such that it 
was represented in standard deviation units (mean = 0, sd = 1). While both methods are 
sound, our approach allows our results to be interpreted in terms of units in reference to 




Gene-based testing and subsequent pathway and biological processes analyses 
through GO and KEGG reveal a potential link to alkaline phosphatase activity (p value = 
1.38 x 10-5), the only pathway to remain significant after permutation testing (permutation 
p value cutoff = 2.11 x 10-4) (Table 3.4). Although not significant, GO identified multiple 
pathways involved with guanosine including dGTP metabolic process (p = 1.36 x 10-3), 
GMP metabolic process (p = 1.39 x 10-3), and guanosine-containing compound metabolic 
process (p = 2.85 x 10-3). KEGG pathway analysis revealed important pathways for proper 
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mitochondrial metabolism including thiamine metabolism (p = 4.88 x 10-3) and folate 
biosynthesis (p = 8.73 x 10-3). Both GO and KEGG additionally identified processes 
involved directly in mitochondrial energy production in proton-transporting two-sector 
ATPase complex, proton-transporting domain (p = 2.83 x 10-3) and oxidative 
phosphorylation (p = 0.033). 
DISCUSSION 
We performed a trans-ethnic GWAS on mtDNA-CN in 79,444 individuals from the 
CHARGE consortium and the UK Biobank. We identified four novel loci as well as 
validated previous loci implicated in mtDNA-CN modulation from a previous GWAS of 
10,000 Chinese women. Furthermore, genes near GWAS loci were implicated in alkaline 
phosphatase activity, a biological process not previously implicated in mitochondrial 
function or mtDNA-CN maintenance. 
Of our genome-wide significant hits, the exonic signal found within NDUFV3 is of 
particular interest as this gene produces one of the three subunits of the flavoprotein 
fraction of NADH dehydrogenase (complex I). Although the function of NDUFV3 is 
unknown, the flavoprotein fraction plays a catalytic role in the oxidation of NADH, directly 
implicating it in mitochondrial function72. Additionally, CCDC71L has been previously 
linked to carotid media thickness, highlighting a potential link to CVD73. Unlike NDUFV3 
and CCDC71L, genes located within the ZNRF4 and REEP3 loci have not been previously 
implicated in mitochondrial function or CVD. 
While alkaline phosphatase has been found to be active within the mitochondria74, 
little is known about its overall role in mitochondrial function. Of interest, elevated levels 
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of alkaline phosphatase in the blood are often the result of liver disease, which has been 
previously associated with mtDNA-CN49,75,76. Although not significant after permutation 
testing, Gene ontology additionally identified several processes involved with the 
metabolism of guanosine. Previous research in rats has identified dGTP represents about 
90% of the total dNTP pool from certain tissues77,78. This dNTP imbalance could lead to 
insertion or proofreading errors during mtDNA replication79. Additionally, the oxidizing 
environment of the mitochondrion could lead to oxidative mutagenesis due to the 
incorporation of 8-oxo-dTP78. Regulation of mtDNA-CN through guanosine metabolism 
could further link copy number to mitochondrial function as mtDNA mutations have been 
previously linked to oxidative stress and mitochondrial dysfunction80,81.  
Although they did not reach the permutation p value threshold, thiamine 
metabolism and folate biosynthesis were identified as two of the top hits in KEGG pathway 
analysis. Thiamine pyrophosphate, a thiamine derivative, is an essential cofactor for 
pyruvate, α-ketoglutarate, and branched-chain ketoacid dehydrogenases82, and thus critical 
for mitochondrial energy production. Folate deficiency mediated through altered folate 
metabolism has been previously linked to improper mitochondrial translation83 , mtDNA 
instability84,85, and thus mitochondrial dysfunction. Furthermore, as the one carbon donor, 
folate metabolism is critical to both DNA86 and histone methylation87, which was also 
identified in our GO analyses. 
In conclusion, we identify and validate several putative modulators of mtDNA-CN 
which warrant further functional follow up. Additionally, our GO and KEGG analyses 
highlight that despite our large sample size, many regulators of mtDNA-CN remain below 
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the genome-wide significance threshold. As such, we propose further investigation into the 
genetic regulators of mtDNA-CN as more data comes available. 
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Table 3.1. Sample characteristics 















Figure 3.1. Trans-ethnic meta-analysis of 79,444 individuals reveals four novel genome-wide significant loci. Random 
effects meta-analysis to account for differences due to ethnicity and mtDNA-CN estimation platform. Filters: Imputation 























Table 3.2. Summary statistics for genome-wide significant hits 
Abbreviations: SNP, single nucleotide polymorphism; Chr, chromosome; Pos, genomic position; Beta, 



















































Table 3.3. Replication of Cai et al. mtDNA-CN GWAS 
Abbreviations: SNP, single nucleotide polymorphism; Beta, effect 












Table 3.4. GO and KEGG pathway and biological process analysis 
Top 7 hits for GO and KEGG analyses. Cutoff for GO analysis: 300 genes. Cutoff for KEGG analysis: 150 genes. p value for over-representation 
of submitted genes within the pathway. Abbreviations: GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; P, p value 
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SUPPLEMENTARY MATERIAL 
UK Biobank whole exome sequencing mtDNA-CN estimation 
 
We started with 49,997 Exome SPB CRAM files (version Jul 2018) downloaded 
from the UKB data repository, and used Samtools (ver1.9) to extract read summary 
statistics (‘idxstats’ command). Linear regression models were used to adjust for total DNA 
and potential technical artifacts. Specifically, we used 10-fold cross validation for variable 
selection, using the ‘leaps’ R package (version 3.0), with an initial model with chrMT read 
count as the dependent variable, and ‘Total’, ‘Mapped’, ‘unknown’, ‘random’, ‘decoy1’ 
and ‘decoy2’ read counts as the independent variables. For each of the independent 
variables, we included a natural spline with df=4 to allow for non-linear effects. The 
independent variables ‘Total’, ‘unknown’, ‘decoy1’ and ‘decoy2’ read counts were 
selected. We then increased the natural spline df to 15, and then used backward selection 
to reduction model complexity, requiring P<0.005 to keep a term in the model. The final 
regression model residuals were generated with the following R (version 3.6.0) code: 
 
resid.mtDNA= residuals(lm(chrMT ~ ns(Total,df=3) + ns(unknown,df=4) + 
ns(decoy1,df=7) + decoy2)) 
 
Residuals from this model were then adjusted for age, with a natural spline df=2, and sex. 
In addition, we performed 10-fold cross validation as described above to identify cell type 
counts to include as covariates in the regression model. The initial model included Platelets, 
Nucleated RBC (yes/no), and log+1 transformations of WBC, RBC, Lymphocytes, 
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Monocytes, Neutrophils, Eosinophils, Basophils, and Nucleated RBC (continuous) counts. 
With the exception of both Nucleated RBC measures, natural splines were included with 
df=3.  The final regression model residuals were generated with the following R (version 
3.6.0) code:  
 
final.mtDNA = residuals(lm(resid.mtDNA ~ sex + ns(age,df=2) + ns(Platelet,df=3) + 
ns(Neutrophil,df=2))) 
 
For these analyses, cell type count outliers were removed based on the following criteria:  
 
Log(WBC) ≤ 1.25 or ≥ 3 
Log(RBC) ≤ 1.4 or ≥ 2 
Platelet ≤10 or ≥ 500 
Log(Lymphocytes) ≤ 0.10 or ≥ 2 
Log(Monocytes) ≥ 0.9 
Log(Neutrophils) ≤ 0.75 or ≥ 2.75 
Log(Eosinophils) ≥ 0.75 







The Atherosclerosis Risk in Communities study (ARIC) recruited 15,792 
individuals between 1987 and 1989 aged 45 to 65 years from 4 US communities88. DNA 
for mtDNA-CN estimation was collected from different visits and was derived from buffy 
coat using the Gentra Puregene Blood Kit (Qiagen). Whole genome sequencing (WGS) 
data was generated at the Baylor College of Medicine Human Genome Sequencing Center 
using Nano or PCR-free DNA libraries on the Illumina HiSeq 2000. Genotyping for the 
Affymetrix Genome-Wide 6.0 Human SNP Array 6.0 was performed in accordance to the 
manufacturers protocol and genotypes were called using Birdseed (version 2).  
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With the availability of two different mtDNA-CN estimation platforms, and previous 
researching highlighting WGS outperforms the Affymetrix array in mtDNA-CN 
estimation64, mtDNA-CN was called first from the 2,923 individuals with WGS data. Copy 
number was additionally estimated in 8,687 from the Affymetrix genotyping array for 
individuals without WGS data. WGS and Affymetrix mtDNA-CN batches were treated as 
separate cohorts due to differences in population distribution. Missing white blood cell 
count data (14.7%) was imputed to the mean. 
 
CHS 
The Cardiovascular Health Study (CHS) is a population-based cohort study of risk 
factors for coronary heart disease and stroke in adults ≥65 years conducted across four field 
centers89. The original predominantly European ancestry cohort of 5,201 persons was 
recruited in 1989-1990 from random samples of the Medicare eligibility lists; 
subsequently, an additional predominantly African-American cohort of 687 persons were 
enrolled for a total sample of 5,888. 
Blood samples were drawn from all participants at their baseline examination and 
DNA was subsequently extracted from available samples. Genotyping was performed at 
the General Clinical Research Center’s Phenotyping/Genotyping Laboratory at Cedars-
Sinai among CHS participants who consented to genetic testing and had DNA available 
using the Illumina 370CNV BeadChip system (for European ancestry participants, in 2007) 
or the Illumina HumanOmni1-Quad_v1 BeadChip system (for African-American 




In 2007, the Framingham Heart Study (FHS) entered a new phase with the conduct 
of genotyping for the FHS SHARe project, for which genotyping was conducted using 
approximately 550,000 SNPs (Affymetrix 500K mapping array plus Affymetrix 50K 
supplemental array) in over 9,300 subjects from the three generations of subjects (including 
over 1500 families). 
 
MESA 
The MESA study recruited 6,814 individuals from 6 US communities free of 
prevalent clinical CVD across 4 ethnicities. Age range at baseline was 45 to 84 and the 
baseline exam occurred between 2000 and 2002. Affymetrix Genome-Wide Human SNP 
Array 6.0 genotype data was available for 8,227 unique individuals within the MESA 
cohort. DNA derived from MESA Family, a subset of MESA, originated from cell lines 
and was excluded resulting in a final sample size of 5,916. DNA for mtDNA-CN analyses 
was isolated from exam 1 peripheral leukocytes using the Gentra Puregene Blood Kit.  
 
ROSMAP 
The Rush Religious Orders Study (ROS), started in 1994, enrolled Catholic priests, 
nuns, and brothers, from about 40 groups in 12 states3. Since January 1994, 1321 
participants completed their baseline evaluation, of whom 1259 were non-Hispanic white. 
The follow-up rate of survivors exceeds 90%. Participants were free of known dementia at 
enrollment, agreed to annual clinical evaluations, and signed both an informed consent and 
 50 
an Anatomic Gift Act form donating their brains at time of death 3. A more detailed 
description of ROS has been published previously3. Participants take a neuropsychological 
test battery. DNA was extracted from whole blood, lymphocytes, or frozen post-mortem 
brain tissue. Genotyping was performed at the Broad Institute’s Center for Genotyping and 
the Translational Genomics Research Institute 2.  
The Rush Memory and AP (MAP), started in 1997, enrolled older men and women 
from assisted living facilities in the Chicago area with no evidence on dementia at baseline 
1. Since October 1997, 1815 participants completed their baseline evaluation, of whom 
1701 were non-Hispanic white people. The follow-up rate of survivors exceeds 90%. 
Participants agreed to annual clinical evaluations, and signed both an informed consent and 
an Anatomic Gift Act form donating their brains at time of death. A more detailed 
description of the MAP has been published previously 1. Participants were invited to take 
a neuropsychological test battery. DNA was extracted from whole blood, lymphocytes, or 
frozen postmortem brain tissue. Genotyping was performed at the Broad Institute’s Center 
for Genotyping and the Translational Genomics Research Institute 2. 
 
SHIP 
The Study of Health in Pomerania (SHIP) is a population-based project in West 
Pomerania, the north-east area of Germany90,91. A sample from the population aged 20 to 
79 years was drawn from population registries. First, the three cities of the region (with 
17,076 to 65,977 inhabitants) and the 12 towns (with 1,516 to 3,044 inhabitants) were 
selected, and then 17 out of 97 smaller towns (with less than 1,500 inhabitants), were drawn 
at random. Second, from each of the selected communities, subjects were drawn at random, 
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proportional to the population size of each community and stratified by age and gender. 
Only individuals with German citizenship and main residency in the study area were 
included. Finally, 7,008 subjects were sampled, with 292 persons of each gender in each 
of the twelve five-year age strata. In order to minimize drop-outs by migration or death, 
subjects were selected in two waves. The net sample (without migrated or deceased 
persons) comprised 6,267 eligible subjects. Selected persons received a maximum of three 
written invitations. In case of non-response, letters were followed by a phone call or by 
home visits if contact by phone was not possible. The SHIP population finally comprised 
4,308 participants (corresponding to a final response of 68.8%). 
 
UKB 
The UK Biobank is a prospective cohort of over 500,000 individuals originating 
from 22 centers within the United Kingdom aged between 40 and 696. Biological samples 
and physical measurements were collected and participants answered extensive 
questionnaires on health. Whole Exome Sequencing data was released in 2019 for 44,805 
self-identified white individuals. 
 
 
Cohort specific QC and GWAS 
 
ARIC 
Genotypes derived from the Affymetrix Genome-Wide Human SNP Array 6.0. 
Individuals were dropped if they refused DNA testing, > 5% missingness, or were 
identified as genetic outliers. Monomorphic SNPs, and SNPs with > 5% missingness were 
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dropped. Individuals with European ancestry were imputed to the Haplotype Reference 
Consortium while individuals of African ancestry were imputed to 1000G (March 2012).  
GWAS was additionally adjusted for 10 principal components. 
 
CHS 
European ancestry Genotypes derived from the Illumina 370CNV chip, ITMAT-
Broad-CARe Illumina iSELECT chip. Individuals were excluded from the sample due to 
the presence of baseline CHD, CHF, peripheral vascular disease, valvular heart disease, 
stroke or TIA, or lack of available DNA. After genotyping, individuals were excluded if 
they had a call rate <=95% or if their genotype was discordant with known sex or prior 
genotyping. SNPs were excluded if they had a call rate <97%, HWE P < 10-5, >2 duplicate 
errors or Mendelian inconsistencies, or heterozygote frequency = 0. 
African ancestry genotypes were derived from the Illumina HumanOmni1-
Quad_v1 BeadChip system. Individuals were excluded from the sample due to lack of 
available DNA. After genotyping, individuals were excluded if they had a call rate <=95% 
or if their genotype was discordant with known sex or prior genotyping. SNPs were 
excluded if they had a call rate <97%, HWE P < 10-5, >1 duplicate error or Mendelian 
inconsistency, or heterozygote frequency = 0. 
African ancestry GWAS was additionally adjusted for 5 principal components. 
 
FHS 
Genotyping derived from the Affymetrix 500K mapping array plus Affymetrix 50K 
supplemental array.  Genotyped SNPs removed based on: HWE p-value of less than 
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0.000001, call rate of less than 96.9%, MAF of less than 0.01, no mapping correctly from 
Build 36 to Build 37 locations, missing a physical location, Mendelian errors greater than 
1000, not being on chromosomes 1-22 or X, duplicates. Imputed to 1000G (March 2012). 
Due to family structure, a linear mixed effects model with fixed polygenic variance 
was used to account for family relationship during the GWAS. 
 
MESA 
Genotypes derived from the Affymetrix Genome-Wide Human SNP Array 6.0. 
Individuals with < 95% genotyping success rate were excluded while SNPs with < 90% 
genotyping success rate were excluded. Imputation was performed to 1000G (March 2012). 
GWAS was additionally adjusted for 4 principal components. 
 
ROSMAP 
Genotypes derived from the Affymetrix Genome-Wide Human SNP Array 6.0. 
Sample-level quality control assessment included exclusion of samples with genotype 
success rate <95%, discordance between inferred and reported gender, and excess 
inter/intraheterozygosity. SNP-level quality control assessment included exclusion of 
SNPs with Hardy-Weighberg equilibrium (p<0.001), MAF < 0.01, genotype call rate < 
0.95, misshap test < 1x10-9. Subsequently, EIGENSTRAT was used to identify and 






Genotypes derived from the Affymetrix Genome-Wide Human SNP Array 6.0. 
Arrays with a call rate below 94%, duplicate samples as identified by estimated IBD as 
well as individuals with reported and genotyped gender mismatch were excluded. The final 
sample call rate was 99.51%.  
GWAS was additionally adjusted for 10 PCs to account for population substructure. 
 
UKB 
Whole exome sequencing, sequencing alignment and variant identification was 
performed as previously described92. Genotypes were available through the Affymetrix 
UK Biobank Axiom array and the Affymetrix UK BiLEVE Axiom array. QC, phasing 
and imputation information have been described previously 
(http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=155580, 
http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=157020). 
Due to its recruitment method and extremely large sample size, as much as 30% of 
the UKB dataset would need to be filtered due to typical relatedness or genetic ancestry 
filters93. To account for this, GWAS was performed using BOLT-LMM (v2.3.2) with the 




Institutional Review Board approvals were obtained by the coordinating center and 
each ARIC study center. The research was conducted in accordance with the principles 
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CHS was approved by institutional review committees at each field center and 
individuals in the present analysis had available DNA and gave informed consent including 
consent to use of genetic information for the study of cardiovascular disease. 
 
FHS 
The Boston University Medical Campus Institutional Review Board approved the 
FHS genome-wide genotyping. 
 
MESA 
MESA All MESA participants provided written and informed consent to participate 
in genetic studies. All study sites received approval to conduct this research from local 
Institutional Review Boards. 
 
ROSMAP 
All participants provided written informed consent and approval was obtained from 






The study has been conducted according to the recommendations of the Declaration 
of Helsinki. The study protocol of SHIP was approved by the medical ethics committee of 
the University of Greifswald. Written informed consent was obtained from each of the 
study participants. 
UKB 
Research was approved by UK Biobank to ensure consistent with participant’s 





































































Supplementary Table 3.1. UK Biobank 
cell counts 
Values are number (%) or mean ± SD.  
Abbreviations: WBC, white blood cell count; 










































Supplementary Figure 3.1. QQ Plot of trans-ethnic meta-





Supplementary Figure 4.2. Ethnicity-specific manhattan plots. Whites (A) and 
Blacks (B) were performed with a random effects meta-analysis to account for 
differences due to mtDNA-CN estimation platform. Chinese (C) and Hispanic (D) 
were present in MESA only. Filters: Imputation quality > 0.6, MAF > 0.005, SNP 












































































































Supplementary Figure 3.3. Ethnicity-specific QQ 
plots. Whites (A), Blacks (B), Chinese (C), and 



















































Chapter 4 : 
Mitochondrial DNA heteroplasmy is associated 
with overall mortality and cardiovascular disease   
 65 
INTRODUCTION 
 Mitochondria play a critical role in energy metabolism as the key organelle 
involved in oxidative phosphorylation. Declines in oxidative capacity represent a key 
feature of mitochondrial dysfunction which is known to play a critical role in the aging 
process and has been previously linked to several aging-related diseases95–97. As a major 
byproduct of oxidative phosphorylation, reactive oxygen species lead to mitochondrial 
DNA damage and heteroplasmy – the presence of multiple distinct mtDNA genomes 
within an individual. Although a proportion of heteroplasmy is inherited (~30%), the 
majority is acquired through somatic mutation (~70%)98 and has been shown to increase in 
prevalence with age99. Furthermore, the frequency of a given heteroplasmy may rise and 
fall over the lifetime of an individual through stochastically biased mtDNA turnover100.  
Given that random mutations, on average, are detrimental due to a lack of selection, 
in addition to the absence of intergenic and intronic space within the mitochondrial 
genome, the accumulation of mitochondrial DNA mutations and heteroplasmy is likely to 
negatively impact mitochondrial function and contribute to mortality and disease. Indeed, 
several studies have shown mtDNA mutations lead to mitochondrial dysfunction and thus 
disease80,101. Additionally, mice with reduced DNA repair activity due to mutations in the 
polG editing domain experienced increased mortality and aging-related phenotypes such 
as premature balding, weight loss and grey hair81.  
Cardiovascular disease (CVD), an umbrella term including several pathologies 
relating to the vasculature, represents one of the leading causes of mortality and morbidity 
with an annual incidence of 800,000 within the United States102. Although CVD is 
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heterogenous, the primary pathological insult for most cases is the chronic inflammatory 
process known as atherosclerosis. Mitochondrial dysfunction, and more specifically 
mtDNA mutations, have been previously linked to the initiation, progression, and severity 
of atherosclerosis. Mitochondrial DNA damage has been shown to be associated with the 
degree of atherosclerosis in human aortas103. Additionally, ApoE knockout mouse models 
of hyperlipidemia developed mtDNA damage in the endothelial wall which preceded 
plaque formation7. Furthermore, bone marrow transplantation from polG knock out mice 
with elevated levels of mtDNA damage into ApoE knockout mice resulted in plaque 
instability, highlighting the potential mechanistic role of heteroplasmy in circulating cells7. 
In the present study, we leverage heteroplasmy calculated across 5,785 individuals 
from the Atherosclerosis Risk in Communities (ARIC) study to evaluate the role of 




The ARIC study recruited 15,792 individuals aged 45 to 65 years from 4 US 
communities between 1987 and 1989. DNA for whole genome sequencing (WGS) was 
collected from different visits and was derived from buffy coat using the Gentra Puregene 
Blood Kit (Qiagen). Analyses were restricted to 6,659 individuals with whole genome 
sequence (WGS) data available from ARIC low-pass WGS efforts (n = 3,604) or WGS 
data sequenced through TOPMed (n = 3,055). We further excluded 874 individuals who 
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had missing phenotype information, potential contamination, insufficient coverage, or 
were duplicates for a final sample size of 5,785 (Supplementary Methods).  
All participants provided written informed consent and all centers obtained 
approval from their respective institutional review boards. 
 
Cardiovascular disease definition and adjudication 
Event adjudication through 2017 in ARIC consisted of expert committee review of 
death certificates, hospital records and telephone interviews. Incident cardiovascular 
disease (CVD) was defined as either incident coronary artery disease (CAD) or incident 
stroke. Incident CAD was defined as first incident MI or death owing to CAD while 
incident stroke was defined as first nonfatal stroke or death due to stroke. Individuals in 
ARIC with prevalent CVD at baseline were excluded from incident analyses. 
 
Whole genome sequencing 
Whole genome sequencing (WGS) data available through TOPMed targeting a 
mean depth of at least 30x was generated using the Illumina HiSeq X Ten at six sequencing 
centers. Sequence reads were mapped to the GRCh38 reference genome using BWA35. 
Variant calling and quality control were performed as previously described104.  
Low pass WGS in ARIC generated at the Baylor College of Medicine Human 
Genome Sequencing Center using Nano or PCR-free DNA libraries on the Illumina HiSeq 
2000 resulted in 6x average sequencing depth. Sequence reads were mapped to the hg19 
reference genome using BWA35. Variant calling and quality control were performed as 
previously described40.  
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To ensure sufficient coverage across the entire genome, reads were remapped to a 
circularized version of the mitochondrial genome. Potential contamination by nuclear 
mitochondrial DNA segments (NUMTs) was limited by removing any mitochondrial reads 
which additionally aligned to the nuclear genome105. GATK indel realigner was run to 




Cox-proportional hazards regression was used to estimate hazard ratios (HRs) for 
mortality and incident disease outcomes. Follow-up time was defined from DNA collection 
date through loss to follow-up, death, or study end point (2017 in ARIC). All statistical 
analyses were performed using R (version 3.3.3). 
RESULTS 
Sample characteristics 
After quality control, the study included 5,785 participants from ARIC (Table 1). 
The mean age of study participants was 58 years, 56.2% of participants were women (n = 
3,249) and 32.8% were black (n = 1,897). 
 
Distribution of heteroplasmy 
The distribution of heteroplasmy was highly skewed with 69.3% of individuals 
having no detectable heteroplasmy at the 5% allele frequency level (n = 4,011) 
(Supplementary Table 4.1). Across all individuals, heteroplasmy was evenly distributed 
 69 
across the mitochondrial genome except for the D-loop region (Figure 4.1). This 





A total of 2,989 deaths were observed in ARIC during 115,626 person-years of 
follow-up. In an age, sex, ethnicity, sequencing depth and DNA collection site adjusted 
cox proportional-hazards inverse weighted meta-analysis of results from both ARIC 
matches we observed a statistically significant association when comparing mortality in 
individuals with and without a heteroplasmic site (HR: 1.19; 95% CI: 1.10-1.28; p value: 
1.09 x 10-5). A more stringent model was applied controlling for traditional risk factors 
including BMI, systolic blood pressure, smoking status, LDL, HDL, triglycerides, 
prevalent diabetes, use of hypertension medication, and history of myocardial infarction, 
resulted in a HR of 1.17 (95% CI: 1.09-1.27; p value: 5.5 x 10-5) (Figure 4.2). Importantly, 
these results are not driven by a single batch as we observe significant HRs of 1.21 and 
1.14 for both the low pass and TOPMed batches in the more stringent model (95% CI: 
1.08-1.35, 1.02-1.26; p value: 6.7 x 10-4, 0.02) (Supplementary Figure 4.1). 
 
Heteroplasmic mutational burden 
To explore the impact of heteroplasmic mutational burden on mortality we explored 
the role of heteroplasmies predicted to be synonymous, nonsynonymous neutral and 
nonsynonymous deleterious. Of the 1,774 heteroplasmies we identified, 160 were 
predicted to be pathogenic as defined by a scaled Combined Annotation Dependent 
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Depletion (CADD) score > 15. In a meta-analysis of both ARIC batches adjusting for all 
demographics and traditional risk factors we observe a HR of 1.26 (95% CI: 1.07-1.47; p 
value: 4.3 x 10-3) when comparing mortality in individuals with at least one deleterious 
heteroplasmy compared to those without any heteroplasmies (Supplemental Figure 2). A 
meta-analysis in individuals with synonymous heteroplasmies observed a HR of 1.15 (95% 
CI: 1.05-1.25; p value: 1.8 x 10-3) (Figure 4.3). 
To further address heteroplasmic mutational burden we investigated the impact of 
having multiple heteroplasmies. A total of 358 individuals were observed to have more 
than one heteroplasmy between both ARIC batches. A meta-analysis adjusting for all 
covariates within ARIC revealed individuals with only one heteroplasmy have a HR of 
1.14 (95% CI: 1.05-1.24; p value: 1.6 x 10-3) compared to individuals with no 
heteroplasmies, while individuals with 2 or more heteroplasmies have a HR of 1.28 (95% 
CI: 1.12-1.47; p value: 4.5 x 10-4) (Figure 4.4). Although these two values are not 
significantly different (p value = 0.15), the directionality of this effect suggests an additive 
effect for heteroplasmic burden. 
 
Incident cardiovascular disease 
 
Within ARIC 1,097 incident CVD events were observed (525 and 572 for ARIC 
low pass and ARIC TOPMed respectively). In an inverse-weighted meta-analysis 
exploring incident CVD events adjusting for age, sex, ethnicity, sequencing depth and 
DNA collection site we observed a HR of 1.07 (95% CI: 0.94-1.21, p value: 0.29) when 
comparing individuals with at least one heteroplasmic site compared to individuals without 
a heteroplasmy. However, once we adjusted for traditional risk factors including BMI, 
systolic blood pressure, smoking status, LDL, HDL, triglycerides, prevalent diabetes and 
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use of hypertension medication we observed a significant HR of 1.14 (95% CI: 1.00-1.29, 
p value: 0.048) (Figure 4.5). The change in significance from the base model to the full 
model most likely highlights the complex nature of mitochondrial dysfunction where there 
is not only a relationship with CVD risk, but also with several traditional risk factors such 
as lipid levels107 or BMI108. 
We further investigated CVD by exploring the impact of heteroplasmy on its 
component parts – coronary artery disease (CAD) and stroke. While we observed no 
significant relationship between heteroplasmy and incident CAD (n = 758) in a meta-
analysis adjusting for traditional risk factors and demographics (HR: 1.06; 95% CI: 0.91-
1.24; p value: 0.46), we did observe a relationship with incident stroke (n = 538) with a HR 
of 1.37 (95% CI: 1.15-1.64; p value: 4.6 x 10-4) (Supplementary Figure 4.3). 
DISCUSSION 
We explored the impact of heteroplasmic burden measured on mortality and 
incident CVD in 5,785 self-identified white and black individuals from the ARIC study. 
Individuals with at least one heteroplasmy were 17% more likely to die during follow up 
and 14% more likely to develop CVD compared to individuals without any heteroplasmy 
independent of traditional risk factors. Furthermore, heteroplasmy was associated with 
mortality independent of CVD deaths (Supplementary Figure 4.4), potentially 
highlighting its importance in other major contributors to mortality such as cancer and 
respiratory disease. While previous research has shown the impact of specific 
heteroplasmies on mortality20, to our knowledge this is the first time overall heteroplasmic 
burden has been shown to be associated with mortality and disease.  
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Our analyses on heteroplasmic mutational burden highlight the predicted 
pathogenicity of a heteroplasmy has a large impact on patient outcome. Counterintuitively, 
synonymous heteroplasmies were also associated with mortality, however research has 
shown silent mutations may modulate transcription and translation109,110. The observed 
impact of synonymous heteroplasmies on mortality could also reflect a hypermutable state 
which may impact nuclear genes. Although event rates were too low to accurately explore 
heteroplasmic mutational burden in CVD, future research should explore this potential 
relationship to further understand the role of heteroplasmy in cardiac disease. 
Although stroke and CAD have overlapping risk factors, our analyses found while 
the presence of heteroplasmy was significantly associated with incident stroke the same 
was not true for CAD. This finding may be driven by the more diverse etiology of stroke 
compared to CAD111. While CAD is mainly driven within the context of coronary 
atherosclerosis, stroke occurs within the setting of atherosclerosis, small vessel disease and 
cardiac embolism. Our results may highlight that heteroplasmy is associated with non-
atherosclerotic cardiovascular disease. 
In conclusion, our study demonstrates heteroplasmy is associated with mortality 
and incident CVD independent of traditional risk factors. Furthermore, our observed 
associations also occur independently of mtDNA-CN, suggesting our mtDNA quantity and 
quality capture different facets of mitochondrial dysfunction (Supplementary Figure 4.5). 
We also observed the effect of heteroplasmy on mortality to be additive and elevated risk 
is present regardless of the predicted pathogenicity of the heteroplasmic site. While this 
study was not designed to address the mechanism of action or a potential causal 
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relationship between heteroplasmy and disease, our results are in line with previous 




























Values are number (%) or mean ± SD  
Abbreviations: SD, standard deviation; BMI, body mass index; BP, 
blood pressure; LDL, low-density lipoprotein; HDL, high-density 
lipoprotein; TG, triglycerides; MI, myocardial infarction 
















































# of Heteroplasmies 
Genomic Size 
Figure 4.1. Distribution of heteroplasmy across mitochondrial 
genome. Heteroplasmy is approximately evenly distributed across 
the mitochondrial genome with regards to genomic size with 


































Figure 4.2. Effect of heteroplasmy on mortality. Inverse-variance weighted meta-
analysis of ARIC low pass sequencing and ARIC TOPMed sequencing batches for 
individuals with at least one heteroplasmy compared to individuals without any 




































Figure 4.3. Effect of synonymous heteroplasmies on mortality. Inverse-variance 
weighted meta-analysis of ARIC low pass sequencing and ARIC TOPMed sequencing 


























Figure 4.4. Effect of multiple heteroplasmies on mortality. Inverse-variance weighted 
meta-analysis of ARIC low pass sequencing and ARIC TOPMed sequencing batches for 
a single heteroplasmy (A) and two or more heteroplasmies (B) compared to individuals 


































Figure 4.5. Effect of multiple heteroplasmies on incident cardiovascular disease. 
Inverse-variance weighted meta-analysis of ARIC low pass sequencing and ARIC 
TOPMed sequencing batches for individuals with at least one heteroplasmy compared to 




Low level contamination caused by sample mix-up, cross-contamination, carry-
over during WGS runs, or postprocessing issues during adapter removal could influence 
heteroplasmy calls. To avoid misinterpretation, mtDNA-server implements an intra-
sample contamination check to identify potentially contaminated samples. Two 
haplogroup profiles are generated; a minor profile based on heteroplasmy calls < 50% 
allele fraction and a major profile based on heteroplasmy calls > 50% allele fraction. 
Homoplasmic variants are included to augment the haplogroup calls. Individuals with 
different haplogroups between minor and major profiles are flagged as potentially 
contaminated by the mtDNA-server pipeline. Flagged samples were manually curated by 
evaluating the phylotree distance between the minor and major profiles, the number of 
heteroplasmies called in a sample, and the average heteroplasmic frequency.  
As additionally methods to identify potential contamination, samples were 
filtered if they contained a large proportion of heteroplasmies which have never been 
observed in phylotree, several heteroplasmies associated with a different haplogroup 
then the one identified for the sample or if a majority of the variants used to call the 
haplogroup for a sample are heteroplasmies.  
Of the 6,659 WGS samples available in ARIC, 223 were filtered due to haplogroup 
contamination, 101 were removed due to poor haplogroup quality, and 473 were 
removed due to missing phenotype information. Additionally, 77 samples which were 
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present in both the low pass data and the TOPMed datasets were removed from the low 
pass batch. Our final sample size for the low pass and TOPMed batches were 2,984 and 








































































































Supplemental Figure 4.1. Effect of having single heteroplasmy on overall mortality. Hierarchical cox proportional-hazards 
model building of traditional risk factors for effect of heteroplasmy on mortality. Hazard ratio (HR) and 95% confidence interval 
(CI) represented on the far right graphically. Abbreviations: BMI, body mass index; BP, blood pressure; LDL, low-density 
lipoprotein; HDL, high-density lipoprotein; TG, triglycerides; MI, myocardial infarction 
 
















Supplemental Figure 4.2. Effect of having single heteroplasmy on overall mortality broken down by predicted mutational 
burden.  Hierarchical cox proportional-hazards model adjusting for age, sex, ethnicity, sequencing depth, body mass index, systolic 
blood pressure, smoking status, low-density lipoprotein, high-density lipoprotein, triglycerides, prevalent diabetes, hypertension 
medication status and history of myocardial infarction. Hazard ratio (HR) and 95% confidence interval (CI) represented on the far 
right graphically. 


























Supplemental Figure 4.3. Effect of heteroplasmy on incident CAD and stroke. 
Inverse-variance weighted meta-analysis of ARIC low pass sequencing and ARIC 
TOPMed sequencing batches for individuals with at least one heteroplasmy compared 


































Supplemental Figure 4.4. Effect of heteroplasmy on non-CVD mortality. Inverse-
variance weighted meta-analysis of ARIC low pass sequencing and ARIC TOPMed 
sequencing batches for individuals with at least one heteroplasmy compared to 






























Supplemental Figure 4.5. mtDNA-CN does not affect impact of heteroplasmy on 
mortality. Hierarchical cox proportional-hazards model adjusting for age, sex, ethnicity, 
sequencing depth, body mass index, systolic blood pressure, smoking status, low-density 
lipoprotein, high-density lipoprotein, triglycerides, prevalent diabetes, hypertension 
medication status and history of myocardial infarction. Hazard ratio (HR) and 95% 
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